Category Archives: Uncategorized

COVID-19 vaccine hesitancy among different population groups in China: a national multicenter online survey

Posted on by

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 19 Feb 2022)

 

COVID-19 vaccine hesitancy among different population groups in China: a national multicenter online survey
COVID-19 vaccine has been available in China since the beginning of the 2021, however, certain numbers of people are reluctant for some reasons to vaccinate. The high vaccine coverage is crucial for controllin…
Authors: Yiman Huang, Xiaoyou Su, Weijun Xiao, Hao Wang, Mingyu Si, Wenjun Wang, Xiaofen Gu, Li Ma, Li Li, Shaokai Zhang, Chunxia Yang, Yanqin Yu and Youlin Qiao
Citation: BMC Infectious Diseases 2022 22:153
Content type: Research article
Published on: 14 February 2022

Mitigating the SARS-CoV-2 Delta disease burden in Australia by non-pharmaceutical interventions and vaccinating children: a modelling analysis

Posted on by

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 19 Feb 2022)

 

Mitigating the SARS-CoV-2 Delta disease burden in Australia by non-pharmaceutical interventions and vaccinating children: a modelling analysis
In countries with high COVID-19 vaccination rates the SARS-CoV-2 Delta variant resulted in rapidly increasing case numbers. This study evaluated the use of non-pharmaceutical interventions (NPIs) coupled with …
Authors: George J. Milne, Julian Carrivick and David Whyatt
Citation: BMC Medicine 2022 20:80
Content type: Research article
Published on: 18 February 2022

Stakeholders’ hopes and concerns about the COVID-19 vaccines in Southeastern Nigeria: a qualitative study

Posted on by

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 19 Feb 2022)

 

Stakeholders’ hopes and concerns about the COVID-19 vaccines in Southeastern Nigeria: a qualitative study
Equitable access and high uptake of safe and effective vaccines is critical to ending the COVID-19 pandemic. To ensure the success of these vaccines, particularly in many developing and under-developed parts o…
Authors: Uchechukwu Madukaku Chukwuocha, Chiagoziem Ogazirilem Emerole, Greg Ndubeze Iwuoha, Ugonma Winnie Dozie, Princewill Ugochukwu Njoku, Chidinma Onyebuchi Akanazu, Precious Okechukwu Eteike and Charlotte Hemingway
Citation: BMC Public Health 2022 22:330
Content type: Research
Published on: 16 February 2022

The lived experiences of a COVID-19 immunization programme: vaccine hesitancy and vaccine refusal

Posted on by

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 19 Feb 2022)

 

The lived experiences of a COVID-19 immunization programme: vaccine hesitancy and vaccine refusal
The COVID-19 pandemic has resulted in a global health emergency and lock-down measures to curb the uncontrolled transmission chain. Vaccination is an effective measure against COVID-19 infections. In Malaysia …
Authors: Nee Nee Chan, Khang Wei Ong, Ching Sin Siau, Kai Wei Lee, Suat Cheng Peh, Shakila Yacob, Yook Chin Chia, Vei Ken Seow and Pei Boon Ooi
Citation: BMC Public Health 2022 22:296
Content type: Research
Published on: 14 February 2022

SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans

Posted on by

Cell
Feb 17, 2022 Volume 185 Issue 4 p579-746
https://www.cell.com/cell/current

 

Articles
SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans
Philip A. Mudd, et al.
Analysis of draining lymph nodes of individuals vaccinated with BNT162b2 mRNA vaccine against SARS-CoV-2 identifies viral-spike-specific follicular helper CD4+ T cells that persist for months and contribute to long-term immunity.

From research ‘on’ to research ‘with’ children about their family lives: A scoping review of ethical and methodological challenges

Posted on by

Child Care, Health and Development
Volume 48, Issue 2, Pages: 177-357 March 2022
https://onlinelibrary.wiley.com/toc/13652214/current

 

REVIEW ARTICLES
From research ‘on’ to research ‘with’ children about their family lives: A scoping review of ethical and methodological challenges
Anne-Catherine Dubois, Magali Lahaye, Isabelle Aujoulat
Pages: 203-216
First Published: 02 December 2021

Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)

Posted on by

Clinical Trials

Volume 19 Issue 1, February 2022
https://journals.sagepub.com/toc/ctja/19/1

Design
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3) Daniel D Murray, Abdel G Babiker, Jason V Baker, Christina E Barkauskas, Samuel M Brown, Christina C Chang, Victoria J Davey, Annetine C Gelijns, Adit A Ginde, Birgit Grund, Elizabeth Higgs, Fleur Hudson, Virginia L Kan, H Clifford Lane, Thomas A Murray, Roger Paredes, Mahesh KB Parmar, Sarah Pett, Andrew N Phillips, Mark N Polizzotto, Cavan Reilly, Uriel Sandkovsky, Shweta Sharma, Marc Teitelbaum, B Taylor Thompson, Barnaby E Young, James D Neaton, Jens D Lundgrenon behalf of the TICO Study Group
First Published October 10, 2021; pp. 52–61

Rapid research response to the COVID-19 pandemic: perspectives from a National Institute for Health Biomedical Research Centre

Posted on by

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 19 Feb 2022]

 

Rapid research response to the COVID-19 pandemic: perspectives from a National Institute for Health Biomedical Research Centre
With over 5 million COVID-19 deaths at the time of writing, the response of research leaders was and is critical to developing treatments to control the global pandemic. As clinical research leaders urgently r…
Authors: Lorna R. Henderson, Helen McShane and Vasiliki Kiparoglou
Citation: Health Research Policy and Systems 2022 20:24
Content type: Commentary
Published on: 19 February 2022

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

Posted on by

JAMA
February 15, 2022, Vol 327, No. 7, Pages 605-693
https://jamanetwork.com/journals/jama/currentissue

 

Original Investigation
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
Emma K. Accorsi, PhD; Amadea Britton, MD; Katherine E. Fleming-Dutra, MD; et al.
free access has active quiz
JAMA. 2022;327(7):639-651. doi:10.1001/jama.2022.0470
This case-control study uses data from the Centers for Disease Control and Prevention Increasing Community Access to Testing platform to estimate the association between receipt of 3 doses of Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273 vaccine, compared with 2 doses or unvaccinated, and symptomatic SARS-CoV-2 infection, stratified by Omicron and Delta variant.

Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period

Posted on by

JAMA
February 15, 2022, Vol 327, No. 7, Pages 605-693
https://jamanetwork.com/journals/jama/currentissue

 

Research Letter
Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period
Lindsey Wang; Pamela B. Davis, MD, PhD; David C. Kaelber, MD, PhD, MPH; et al.
free access has active quiz
JAMA. 2022;327(7):678-680. doi:10.1001/jama.2022.0210
This study examines breakthrough SARS-CoV-2 infections, hospitalizations, and mortality in March-August 2021, when the Delta variant predominated, among a general US cohort vaccinated with mRNA-1273 or BNT162b2.

COVID-19 Therapeutics for Nonhospitalized Patients

Posted on by

JAMA
February 15, 2022, Vol 327, No. 7, Pages 605-693
https://jamanetwork.com/journals/jama/currentissue

 

Viewpoint
COVID-19 Therapeutics for Nonhospitalized Patients
Rajesh T. Gandhi, MD; Preeti N. Malani, MD, MSJ; Carlos del Rio, MD
JAMA. 2022;327(7):617-618. doi:10.1001/jama.2022.0335
This Viewpoint provides a summary of currently available therapeutics for nonhospitalized patients with COVID-19 in the setting of the Omicron variant including principles for equitable allocation.

Intellectual property rights trump the right to health: Canada’s Access to Medicines Regime and TRIPs flexibilities in the context of Bolivia’s quest for vaccines

Posted on by

Journal of Global Ethics
Volume 17, Issue 3, 2021
http://www.tandfonline.com/toc/rjge20/current

 

Article
Intellectual property rights trump the right to health: Canada’s Access to Medicines Regime and TRIPs flexibilities in the context of Bolivia’s quest for vaccines
James Crombie
Pages: 353-366
Published online: 16 Dec 2021

Describing the Epidemiology of COVID-19 in Nigeria: An Analysis of the First Year of the Pandemic

Posted on by

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 33, Number 1, February 2022
https://muse.jhu.edu/issue/47329

 

Table of Contents
Original Papers
Describing the Epidemiology of COVID-19 in Nigeria: An Analysis of the First Year of the Pandemic
Obinna Oleribe, Olatayo Olawepo, Oliver Ezechi, Princess Osita-Oleribe, Michael Fertleman, Simon D. Taylor-Robinson
pp. 33-46
DOI: 10.1353/hpu.2022.0005

Parents’ Behaviors and Experiences Associated with Four Vaccination Behavior Groups for Childhood Vaccine Hesitancy

Posted on by

Maternal and Child Health Journal
Volume 26, issue 2, February 2022
https://link.springer.com/journal/10995/volumes-and-issues/26-2

 

Articles
Parents’ Behaviors and Experiences Associated with Four Vaccination Behavior Groups for Childhood Vaccine Hesitancy
Morgan E. Ellithorpe, Robyn Adams, Fashina Aladé
Content type: OriginalPaper
Published: 07 January 2022
Pages: 280 – 288

Pandemics disable people — the history lesson that policymakers ignore

Posted on by

Nature
Volume 602 Issue 7897, 17 February 2022
https://www.nature.com/nature/volumes/602/issues/7897

 

Comment | 16 February 2022
Pandemics disable people — the history lesson that policymakers ignore
Influenza, polio and more have shown that infections can change lives even decades later. Why the complacency over possible long-term effects of COVID-19?
Laura Spinney

Recent Orange and Purple Book legislation suggests a need to bridge drug and biologic patent regimes

Posted on by

Nature Biotechnology
Volume 40 Issue 2, February 2022
https://www.nature.com/nbt/volumes/40/issues/2

 

Patents | 15 February 2022
Recent Orange and Purple Book legislation suggests a need to bridge drug and biologic patent regimes
Additional changes could make the registries of drug patents published by the FDA, called the Orange and Purple Books, more useful and reduce barriers to effective competition from generic and biosimilar drugs.
Bryan S. Walsh, Jonathan J. Darrow, Aaron S. Kesselheim

Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children

Posted on by

njp Vaccines
https://www.nature.com/npjvaccines/
[Accessed 19 Feb 2022]

 

7, Article number: 19 (2022]
Open access
Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children
Rahnuma Wahid. Laina Mercer, John O. Konz
Abstract
Novel oral poliovirus vaccine type 2 (nOPV2) is being developed to reduce the rare occurrence of disease and outbreaks associated with the genetic instability of the Sabin vaccine strains. Children aged 1 to 5 years were enrolled in two related clinical studies to assess safety, immunogenicity, shedding rates and properties of the shed virus following vaccination with nOPV2 (two candidates) versus traditional Sabin OPV type 2 (mOPV2). The anticipated pattern of reversion and increased virulence was observed for shed Sabin-2 virus, as assessed using a mouse model of poliovirus neurovirulence. In contrast, there were significantly reduced odds of mouse paralysis for shed virus for both nOPV2 candidates when compared to shed Sabin-2 virus. Next-generation sequencing of shed viral genomes was consistent with and further supportive of the observed neurovirulence associated with shed Sabin-2 virus, as well as the reduced reversion to virulence of shed candidate viruses. While shed Sabin-2 showed anticipated A481G reversion in the primary attenuation site in domain V in the 5’ untranslated region to be associated with increased mouse paralysis, the stabilized domain V in the candidate viruses did not show polymorphisms consistent with reversion to neurovirulence. The available data from a key target age group for outbreak response confirm the superior genetic and phenotypic stability of shed nOPV2 strains compared to shed Sabin-2 and suggest that nOPV2 should be associated with less paralytic disease and potentially a lower risk of seeding new outbreaks.

Media attention and Vaccine Hesitancy: Examining the mediating effects of Fear of COVID-19 and the moderating role of Trust in leadership

Posted on by

PLoS One
http://www.plosone.org/
[Accessed 19 Feb 2022]

 

Research Article
Media attention and Vaccine Hesitancy: Examining the mediating effects of Fear of COVID-19 and the moderating role of Trust in leadership
Lulin Zhou, Sabina Ampon-Wireko, Xinglong Xu, Prince Edwudzie Quansah, Ebenezer Larnyo
Research Article | published 18 Feb 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0263610

Infection and vaccination status of COVID-19 among healthcare professionals in academic platform: Prevision vs. reality of Bangladesh context

Posted on by

PLoS One
http://www.plosone.org/
[Accessed 19 Feb 2022]

 

Infection and vaccination status of COVID-19 among healthcare professionals in academic platform: Prevision vs. reality of Bangladesh context
Bilkis Banu, Nasrin Akter, Sujana Haque Chowdhury, Kazi Rakibul Islam, Md. Tanzeerul Islam, Sarder Mahmud Hossain
Research Article | published 18 Feb 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0263078

Hepatitis vaccination adherence and completion rates and factors associated with low compliance: A claims-based analysis of U.S. adults

Posted on by

PLoS One
http://www.plosone.org/
[Accessed 19 Feb 2022]

 

Hepatitis vaccination adherence and completion rates and factors associated with low compliance: A claims-based analysis of U.S. adults
Joyce LaMori, Xue Feng, Christopher D. Pericone, Marco Mesa-Frias, Obiageli Sogbetun, Andrzej Kulczycki
Research Article | published 17 Feb 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0264062

Determinants of vaccine coverage and timeliness in a northern Pakistani village

Posted on by

PLoS One
http://www.plosone.org/
[Accessed 19 Feb 2022]

 

Determinants of vaccine coverage and timeliness in a northern Pakistani village
Alexandra F. Jamison, Benjamin J. J. McCormick, Ejaz Hussain, Elizabeth D. Thomas, Syed Iqbal Azam, Chelsea L. Hansen, Zeba A. Rasmussen
Research Article | published 17 Feb 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0263712

To vax or not to vax: Predictors of anti-vax attitudes and COVID-19 vaccine hesitancy prior to widespread vaccine availability

Posted on by

PLoS One
http://www.plosone.org/
[Accessed 19 Feb 2022]

 

To vax or not to vax: Predictors of anti-vax attitudes and COVID-19 vaccine hesitancy prior to widespread vaccine availability
Hannah A. Roberts, D. Angus Clark, Claire Kalina, Carter Sherman, Sarah Brislin, Mary M. Heitzeg, Brian M. Hicks
Research Article | published 15 Feb 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0264019

Global systemic risk and resilience for novel coronavirus in postpandemic era

Posted on by

Risk Analysis
Volume 42, Issue 1 January 2022
https://onlinelibrary.wiley.com/toc/15396924/current

 

Special Issue: Global Systemic Risk and Resilience for Novel Coronavirus in Post‐Pandemic Era
EDITORIAL
Free Access
Global systemic risk and resilience for novel coronavirus in postpandemic era
Desheng Dash Wu, Jade Mitchell, James H. Lambert
Pages: 1-4
First Published: 12 February 2022

Empower with evidence

Posted on by

Science
Volume 375| Issue 6582| 18 Feb 2022
https://www.science.org/toc/science/current

 

Editorial
Empower with evidence
Susan G. Amara
[Excerpt]
This week (17 to 20 February), the virtual annual meeting of the American Association for the Advancement of Science (AAAS, the publisher of Science) will address the challenges of building the public’s trust and understanding of science by illuminating both great science and innovative initiatives in advocacy, education, and policy. The theme, “Empower with Evidence,” speaks to the critical importance of decision-making, policy-making, and interventions that are grounded in knowledge and facts, not opinions—or worse, misinformation.
The ability of science to transform the world is increasingly threatened by misinformation that is jeopardizing trust in science. As highlighted in Science last week, the world’s information ecosystem is rapidly changing, and online environments have become a powerful open marketplace of facts, ideas, and opinions—where the meaningfulness of science is easily drowned out by the noise.
Solutions to this dilemma include training students and professional scientists to more effectively translate their work to the public, harnessing insights from the behavioral and social sciences to better engage with the public, and working with social media platforms to improve information delivery to a broader audience. These are important efforts, but do they get to the root of the problem?…

Sovereignty, sanctions, and data sharing under international law

Posted on by

Science
Volume 375| Issue 6582| 18 Feb 2022
https://www.science.org/toc/science/current

 

Policy Forum
Sovereignty, sanctions, and data sharing under international law
BY Michelle Rourke, Mark Eccleston-Turner, Stephanie Switzer
17 Feb 2022: 724-726
Pathogen samples and scientific data are bargaining chips in a global argument about who gets what in a pandemic
Abstract
In September 2021, after inaugurating the Berlin-based World Health Organization (WHO) Hub for Pandemic and Epidemic Intelligence, German Health Minister Jens Spahn indicated that sanctions might be an appropriate tool to deal with WHO member states that do not cooperate on data sharing during disease outbreaks. Tedros Adhanom Ghebreyesus, director general of the WHO, affirmed this, stating that “exploring the [idea of ] sanctions may be important” in cases where collaboration fails (1). Such comments indicate that the WHO Hub has been designed without much consideration of data sovereignty and “access and benefit sharing” (ABS) debates occurring across multiple United Nations (UN) bodies, including the WHO. Threats of sanctions do little to promote the ideals of equity and solidarity often touted as foundational to global health governance. They entrench the idea that pathogen samples and associated data are “bargaining chips” rather than vital inputs to public health research and pandemic response.

Impact of the COVID-19 pandemic on pediatric and adolescent vaccinations and well child visits in the United States: A database analysis

Posted on by

Vaccine
Volume 40, Issue 5 Pages 691-832 (31 January 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/5

 

Research article Open access
Impact of the COVID-19 pandemic on pediatric and adolescent vaccinations and well child visits in the United States: A database analysis
Stephanie A. Kujawski, Lixia Yao, H. Echo Wang, Cristina Carias, Ya-Ting Chen
Pages 706-713

Optimizing vaccine distribution via mobile clinics: a case study on COVID-19 vaccine distribution to long-term care facilities

Posted on by

Vaccine
Volume 40, Issue 5 Pages 691-832 (31 January 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/5

 

Research article Open access
Optimizing vaccine distribution via mobile clinics: a case study on COVID-19 vaccine distribution to long-term care facilities
Samta Shukla, Francois Fressin, Michelle Un, Henriette Coetzer, Sreekanth K. Chaguturu
Pages 734-741

Vaccine timeliness and prevalence of undervaccination patterns in children ages 0–19 months, U.S., National Immunization Survey-Child 2017

Posted on by

Vaccine
Volume 40, Issue 5 Pages 691-832 (31 January 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/5

 

Research article Abstract only
Vaccine timeliness and prevalence of undervaccination patterns in children ages 0–19 months, U.S., National Immunization Survey-Child 2017
Rain E. Freeman, Juthika Thaker, Matthew F. Daley, Jason M. Glanz, Sophia R. Newcomer
Pages 765-773

Pre-Print Servers

Posted on by

Pre-Print Servers

 

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 19 Feb 2022]

Research Article metrics
Revised
Setting up child health and mortality prevention surveillance in Ethiopia [version 2; peer review: 1 approved, 1 approved with reservations]
Anna C. Seale, Nega Assefa, Lola Madrid, Stefanie Wittmann, Hanan Abdurahman, Nardos Teferi, Letta Gedefa, Alexander Mohamed, Natnael Debela, Tseyon Tesfaye, Tigistu Samuel, Mehret Dubale, Hiwot Yigzaw, Eyoel Taye, Workalemahu Bekele, Caroline Ackley, Gutema Imana Keno, Yosef Zegeye, Zerihun Girma, Ketema Degefa, Berhanu Damisse, Adugna Tadesse, Mohammed Aliyi, Gurmu Feyissa, Yenenesh Tilahun, Getahun Wakwaya, Bizunesh Sintayehu, Getamesay Abayneh, Addisu Alemu, Emmanuel Azore, Joe Oundo, Zelalem T Mariam, Dadi Marami, Mulu Berihun, Mussie Berhanu, Mahlet Mekonnen, Andualem Alemayehu, Nana Sarkodie-Mensah, Shirine Voller, Boniface Jibendi, Abraham Aseffa, Taye Balcha, Robert F. Breiman, Scott Dowell, Asnake Worku, Tsigereda Kifle, Ebba Abate, Yadeta Dessie, J. Anthony G. Scott
Peer Reviewers Godfrey M. Bigogo; Bernt Lindtjørn
Funders
Bill and Melinda Gates Foundation
Wellcome
LATEST VERSION PUBLISHED 14 Feb 2022

 

medRxiv
https://www.medrxiv.org/content/about-medrxiv
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints – complete but unpublished manuscripts – that describe human health research conducted, analyzed, and interpreted according to scientific principles…

Adolescent vaccination with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine and effectiveness against COVID-19: national test-negative case-control study, England
Annabel A Powell, Freja Kirsebom, Julia Stowe, Kelsey McOwat, Vanessa Saliba, Mary E Ramsay, Jamie Lopez Bernal, Nick Andrews, Shamez N Ladhani
medRxiv 2021.12.10.21267408; doi: https://doi.org/10.1101/2021.12.10.21267408

Meta-analyses on SARS-CoV-2 Viral Titers in Wastewater and Their Correlations to Epidemiological Indicators
David Mantilla-Calderon, Kaiyu (Kevin) Huang, Aojie Li, Kaseba Chibwe, Xiaoqian Yu, Yinyin Ye, Lei Liu, Fangqiong Ling
medRxiv 2022.02.14.22270937; doi: https://doi.org/10.1101/2022.02.14.22270937

City-wide wastewater genomic surveillance through the successive emergence of SARS-CoV-2 Alpha and Delta variants
F.S. Brunner, M.R. Brown, I. Bassano, H. Denise, M.S. Khalifa, M. Wade, J.L. Kevill, D.L. Jones, K. Farkas, A.R. Jeffries, The COVID-19 Genomics UK (COG-UK) Consortium, E. Cairns, C. Wierzbicki, S. Paterson
medRxiv 2022.02.16.22269810; doi: https://doi.org/10.1101/2022.02.16.22269810

Racial discrimination, low trust in the health system, and COVID-19 vaccine uptake: a longitudinal observational study of 633 UK adults from ethnic minority groups
Elise Paul, Daisy Fancourt, Mohammad Razai
medRxiv 2021.08.26.21262655; doi: https://doi.org/10.1101/2021.08.26.21262655

SARS-CoV-2 infection in Africa: A systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021
HC Lewis, H Ware, M Whelan, L Subissi, Z Li, X Ma, A Nardone, M Valenciano, B Cheng, K Noel, C Cao, M Yanes-Lane, B Herring, A Talisuna, N Nsenga, T Balde, DA Clifton, M Van Kerkhove, DL Buckeridge, N Bobrovitz, J Okeibunor, RK Arora, I Bergeri, the UNITY Studies Collaborator Group
medRxiv 2022.02.14.22270934; doi: https://doi.org/10.1101/2022.02.14.22270934

Assessing the Profile of Unvaccinated COVID-19 Individuals in African American and Latinx Communities in Eastern Pennsylvania
Kenya M. Colvin, Kennedy S. Camara, Latasha S. Adams, Adline P. Sarpong, Danielle G. Fuller, Sadie E. Peck, Anthony S. Ramos, Ariana L. Acevedo, Meless A. Badume, Shae-lyn A. Briggs, Tiffany N. Chukwurah, Zanett Davila-Gutierrez, James A. Ewing, Jemimah O. Frempong, Amirah A. Garrett, Steven J. Grampp, Jahasia W. Gillespie, Emmanuel J. Herrera, Emis J. Maddox, John C. Pelaez, Olivia L. Quartey, Fanny Rodriguez, Luis A. Vasquez, Brian J. Piper, Swathi Gowtham
medRxiv 2022.02.11.22270504; doi: https://doi.org/10.1101/2022.02.11.22270504

Co-infection with SARS-COV-2 Omicron and Delta Variants Revealed by Genomic Surveillance
Rebecca J Rockett, Jenny Draper, Mailie Gall, Eby M Sim, Alicia Arnott, Jessica E Agius, Jessica Johnson-Mackinnon, Elena Martinez, Alexander P Drew, Clement Lee, Christine Ngo, Marc Ramsperger, Andrew N Ginn, Qinning Wang, Michael Fennell, Danny Ko, Linda Huston, Lukas Kairaitis, Edward C Holmes, Matthew N O’Sullivan, Sharon C-A Chen, Jen Kok, Dominic E Dwyer, Vitali Sintchenko
medRxiv 2022.02.13.22270755; doi: https://doi.org/10.1101/2022.02.13.22270755

Unpacking COVID-19 and Conspiracy Theories in the UK Black Community
Tushna Vandrevala, Jane Hendy, Kristin Hanson, Lailah Alidu, Aftab Ala
medRxiv 2022.02.12.22270438; doi: https://doi.org/10.1101/2022.02.12.22270438

Wellcome Open Research [to 19 Feb 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 19 Feb 2022]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Research Article metrics
Revised
Date of introduction and epidemiologic patterns of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Mogadishu, Somalia: estimates from transmission modelling of satellite-based excess mortality data in 2020 [version 2; peer review: 1 approved, 1 approved with reservations]
Mihaly Koltai, Abdihamid Warsame, Farah Bashiir, Terri Freemantle, Chris Reeve, Chris Williams, Mark Jit, Stefan Flasche, Nicholas G. Davies, CMMID COVID-19 working group, Ahmed Aweis, Mohamed Ahmed, Abdirisak Dalmar, Francesco Checchi
Peer Reviewers Zindoga Mukandavire; Bhaswar Ghosh
Funders
Wellcome Trust
Foreign, Commonwealth and Development Office
UK Research and Innovation
LATEST VERSION PUBLISHED 18 Feb 2022

Systematic Review metrics AWAITING PEER REVIEW
Influences on User Trust in Healthcare Artificial Intelligence: A Systematic Review [version 1; peer review: awaiting peer review]
Eva Jermutus, Dylan Kneale, James Thomas, Susan Michie
Peer Reviewers Invited
Funders
Wellcome Trust
Economic and Social Research Council
PUBLISHED 18 Feb 2022

Research Article metrics
Revised
Lessons learned and lessons missed: impact of the coronavirus disease 2019 (COVID-19) pandemic on all-cause mortality in 40 industrialised countries and US states prior to mass vaccination [version 2; peer review: 1 approved, 1 approved with reservations]
Vasilis Kontis, James E. Bennett, Robbie M. Parks, Theo Rashid, Jonathan Pearson-Stuttard, Perviz Asaria, Bin Zhou, Michel Guillot, Colin D. Mathers, Young-Ho Khang, Martin McKee, Majid Ezzati
Peer Reviewers Rajeev Gupta; Virgilio Gómez-Rubio
Funders
Wellcome Trust
British Heart Foundation
US Environmental Protection Agency
LATEST VERSION PUBLISHED 15 Feb 2022

Think Tanks

Posted on by

Think Tanks
 
 
Brookings
http://www.brookings.edu/
Accessed 19 Feb 2022
How We Rise
The pandemic showed why social and structural determinants of health matter. Now it’s time for policymakers to act.
Anthony Barr and Ariel Gelrud Shiro
Friday, February 18, 2022

Future Development
Harnessing technology for pandemic preparedness demands system reform
Yolanda Botti-Lodovico
Friday, February 18, 2022

Africa in Focus
What’s next for R&D in health for Africa?
Dr. Christian Happi
Thursday, February 17, 2022

Future Development
Getting out of the coronavirus economic contraction
Indermit Gill, M. Ayhan Kose, and Dana Vorisek
Wednesday, February 16, 2022

Africa in Focus
The future of vaccine manufacturing in Africa
Chidi Victor Nweneka and Tolu Disu
Monday, February 14, 2022
 
 
Center for Global Development [to 19 Feb 2022]
https://www.cgdev.org/
Accessed 19 Feb 2022
Operationalizing the African Medicines Agency: The Strategic Design of a Regional Platform for Medicines Regulation
Event 2/24/22
As of November 5, 2021, the African Union signed into force its second specialized health agency: the African Medicines Agency (AMA). More than two years after its introduction, the AMA treaty has now been ratified by 17 African Union member countries – two more than was required – and has been signed by many more, making it the latest regional partnership to strengthen capacity for medicines regulation and facilitate regulatory harmonization across the African continent in order to improve access to safe, effective, and quality-assured medicines. With high-level support secured, attention now must shift to strategic questions of how to operationalize the AMA and set it up for success.

African Vaccine Manufacturing with EU support: Addressing Demand Uncertainties is Crucial for Success
February 15, 2022
Last week, the European Union and its member states placed a “European global health strategy” at the top of their shared agenda. And as part of the EU-Africa summit this week in Brussels, the EU is highlighting its support for regional manufacturing of COVID-19 vaccine via the African Union’s Partnership for African Vaccine Manufacturing (PAVM) as a major piece of the overall agenda.
Amanda Glassman and Prashant Yadav

Decolonising EU-Africa Relations Is A Pre-Condition For A True Partnership Of Equals
February 15, 2022
The upcoming EU-Africa summit is a welcome step towards upgrading ties. But a true partnership of equals between the two continents requires a decolonization of relations between the EU and Africa.
Shada Islam
 
 
Chatham House [to 19 Feb 2022]
https://www.chathamhouse.org/
Accessed 19 Feb 2022
[No new digest content identified]

 
 
CSIS
https://www.csis.org/
Accessed 19 Feb 2022
Upcoming Event
Overcoming Gender-Related Barriers to Immunization Services
March 8, 2022

 
 

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 19 Feb 2022
February 17, 2022 News Release
Analysis Finds The Share of Nursing Home Staff Who Have Been Vaccinated Against COVID-19 Varies Substantially by State
The share of nursing home staffers who have been fully vaccinated against COVID-19 varies considerably by state, from 70 percent in Ohio to 99 percent in Maine, Rhode Island, New York and Massachusetts, a new KFF analysis finds. The national average is 84 percent. The analysis of federal nursing home…
 
 
Rand [to 19 Feb 2022] ############
https://www.rand.org/pubs.html
Reports, Selected Journal Articles
Report
Incorporating Complementary and Integrative Health Providers in the Public Health Pandemic Response: Lessons from COVID-19 and Recommendations for the Future from a Multidisciplinary Expert Panel
Complementary and integrative health providers have been an underutilized public health asset in the response to the COVID-19 pandemic. This report seeks to inform how they can be better integrated into future responses to public health emergencies.
Feb 17, 2022
Ian D. Coulter, Margaret D. Whitley, Raheleh Khorsan, Patricia M. Herman

Report
COVID-19 Genomics UK (COG-UK) Consortium: Final Report
RAND Europe evaluated how the COVID-19 Genomics UK (COG-UK) Consortium contributed to the pandemic response in the United Kingdom and examined the role of pathogen genomics research and sequencing networks in pandemic response.
Feb 15, 2022
Sonja Marjanovic, Robert J. Romanelli, Gemma-Claire Ali, Brandi Leach, Margaretha Bonsu, Daniela Rodriguez-Rincon, Tom Ling

Vaccines and Global Health: The Week in Review :: 12 February 2022

Posted on by

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

– pdf version:  A pdf of the current issue is available here:

vaccines-and-global-health_the-week-in-review_12-feb-2022Download

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

ACT-Accelerator calls for fair share-based financing of US$ 23 billion to end pandemic as global emergency in 2022

Posted on by

ACT-Accelerator calls for fair share-based financing of US$ 23 billion to end pandemic as global emergency in 2022
World leaders launch campaign to meet the US$ 16 billion ACT-Accelerator funding gap and US$ 6.8 billion in-country delivery costs to take vital steps towards ending the pandemic as a global emergency in 2022.
The ACT-Accelerator initiative works to overcome vast global inequities by providing low- and middle-income countries with access to COVID-19 tests, treatments, vaccines and personal protective equipment.
The ACT-Accelerator agencies urgently need new funding to scale up their work to develop and deliver the COVID-19 countermeasures essential to address the threat of Omicron and prevent even more dangerous variants from emerging.
A diverse group of governments have agreed on a new financing framework developed in support of the ACT-Accelerator, which makes ‘fair share’ requests of richer countries to contribute to the global fight against COVID-19.

GENEVA, February 9, 2022 – World leaders will today launch a call to end the pandemic as a global emergency in 2022 by funding the Access to COVID-19 Tools (ACT) Accelerator, a partnership of leading agencies that is providing low and middle-income countries with tests, treatments, vaccines, and personal protective equipment.

With a significant proportion of the global population still unable to get vaccinated, tested or treated, US$ 16 billion in grant funding is urgently required from governments to fund the work of the ACT-Accelerator agencies. This investment will allow them to procure essential tools to fight COVID-19 and provide them to low- and middle-income countries.

The ACT-Accelerator is calling for the support of higher income countries, at a time when vast global disparities in access to COVID-19 tools persist. Over 4.7 billion COVID-19 tests have been administered globally since the beginning of the pandemic. However, only about 22 million tests have been administered in low-income countries, comprising only 0.4% of the global total. Only 10% of people in low-income countries have received at least one vaccine dose. This massive inequity not only costs lives, it also hurts economies and risks the emergence of new, more dangerous variants that could rob current tools of their effectiveness and set even highly-vaccinated populations back many months…